RecruitingPhase 4

Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism

Denmark24 participantsStarted 2025-08

Plain-language summary

The aim of this study is to investigate the effect of daily treatment with Indapamide for 14 days on urinary calcium excretion in patients with post surgical hypoparathyroidisme.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Chronic post surgical hypoparathyroidism diagnosed \> 1 year ago
✓. Age ≥ 18 years
✓. Require treatment with active vitamin D ≥ 1 µg/day
✓. Ionized plasma calcium between 1.15-1.25 mmol/L
✓. 25(OH)D vitamin ≥ 50 nmol/L
✓. Plasma magnesium \> 0.65 mmol/L
✓. Able to read and understand Danish
✓. Willing and able to sign the informed consent form

Exclusion criteria

✕. Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m3
✕. Active cancer or former (except thyroid and basal cell skin) cancer treatment \< 1 year ago
✕. Pregnancy, pregnancy plans, or breastfeeding \< 1 year ago
✕. Abnormal arterial pressure at time of screening defined as symptomatic hypotension or systolic blood pressure \< 100 mmHg
✕. Plasma potassium \< 3.5 mmol/L
✕. Any current disease that might affect the calcium metabolism such as but not limited to:
✕. Recent prolonged immobility
✕. Untreated diabetes (HbA1c \> 53 mmol/mol)

What they're measuring

Urinary calcium excretion

Timeframe: Day 15

Trial details

NCT IDNCT07034677

SponsorLars Rejnmark

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

Contact for this trial

Sarah Thornhøj, MD

+4540491821 sarthorn@rm.dk

View on ClinicalTrials.gov More Hypoparathyroidism Post-surgical trials